Vivos Inc. (RDGL)
OTCMKTS · Delayed Price · Currency is USD
0.0690
-0.0008 (-1.15%)
Feb 9, 2026, 11:53 AM EST
Vivos Revenue
Vivos had revenue of $1.88K in the quarter ending September 30, 2025, a decrease of -62.42%. This brings the company's revenue in the last twelve months to $48.62K, up 111.40% year-over-year. In the year 2024, Vivos had annual revenue of $28.00K with 43.56% growth.
Revenue (ttm)
48.62K
Revenue Growth
+111.40%
P/S Ratio
646.46
Revenue / Employee
48.62K
Employees
1
Market Cap
31.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.00K | 8.50K | 43.56% |
| Dec 31, 2023 | 19.50K | -17.00K | -46.57% |
| Dec 31, 2022 | 36.50K | 21.61K | 145.17% |
| Dec 31, 2021 | 14.89K | 7.89K | 112.67% |
| Dec 31, 2020 | 7.00K | -2.50K | -26.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biotricity | 15.08M |
| QHSLab | 2.61M |
| PetVivo Holdings | 1.41M |
| Positron | 486.45K |
| Guided Therapeutics | 178.00K |
| CS Diagnostics | 98.73K |
| ALR Technologies SG | 25.54K |
| REMSleep Holdings | 6.73K |
Vivos News
- 7 days ago - Vivos Inc Updates Human Therapy Progress in India - GlobeNewsWire
- 13 days ago - Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals - GlobeNewsWire
- 7 weeks ago - Vivos Inc Summarizes Progress in its Animal Therapy Division - GlobeNewsWire
- 7 weeks ago - Vivos Inc Summarzes Preogress in its Animal Therapy Division - GlobeNewsWire
- 3 months ago - Vivos Inc. Issues Shareholder Update Letter - GlobeNewsWire
- 3 months ago - Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics - GlobeNewsWire
- 3 months ago - Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D. - GlobeNewsWire
- 4 months ago - Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India - GlobeNewsWire